New York—A new bioelectronic medicine approach to treat autoimmune diseases using vagus nerve stimulation (VNS) demonstrated strong therapy adherence and significant reduction in rheumatoid arthritis after 24 months of therapy.
“The bioelectronic medicine and VNS system used in this study are very different and [a] novel approach to treating autoimmune disease by directly activating the vagus nerve,” said David Chernoff, MD, the chief medical officer at SetPoint Medical Corp.,